The persistent challenges of "difficult access to medical care and diagnosis" represent a fundamental bottleneck hindering the improvement of public health standards globally. The lengthy training cycle for top-tier diagnostic physicians and the uneven distribution of high-quality medical resources have resulted in a long-standing deficit in diagnostic efficiency. The potential to develop AI-powered diagnostic systems that rival the expertise of leading specialists offers a solution to fundamentally address structural issues in healthcare resource allocation and extend high-quality diagnostic services to broader populations. Driven by this core premise, global capital is flowing in and supportive policies are being implemented worldwide, positioning AI healthcare as a focal point in the new wave of technological competition. On March 20th, Hangzhou Diagens Biotechnology Co., Ltd. (02526), a leader in the AI healthcare sector, made its formal debut on the Hong Kong Stock Exchange, marking a significant milestone as the first listed company centered on a large-scale medical imaging model.
DIAGENS-B addresses this critical challenge by leveraging its globally unique, trillion-parameter medical imaging foundation model. This technology aims to provide a "China solution" to the issues of healthcare access and diagnosis by utilizing AI to perform diagnostic functions across a majority of medical scenarios, potentially reducing reliance on human doctors. This listing is not only a key milestone in the company's capitalization journey but also sends a clear signal to the market: AI healthcare companies possessing high technological barriers, clear monetization pathways, and稀缺性 value are increasingly becoming core targets for capital allocation.
**1. Scarcity and Uniqueness: A 7-8 Year Head Start** Within the valuation framework for technology innovation firms, scarcity and differentiation are central to assessing long-term value. DIAGENS-B's稀缺性 is not limited to a single technological advantage but is built upon a comprehensive competitive barrier spanning underlying technology, business model, and capital market positioning. The company has established a difficult-to-replicate first-mover advantage through a technology lead of 7-8 years, extensive clinical data accumulation, full-process capabilities, and capital market synergy.
Its business model advantage stems from being China's sole provider of an end-to-end AI medical imaging solution. Unlike many peers focused solely on software, DIAGENS-B has built an integrated ecosystem encompassing "foundation model – intelligent medical devices – reagents and consumables – large model services." This model enables hardware-software synergy and integrated consumable services, creating a dual-drive business格局 through product sales and technology licensing, deeply aligned with client needs. Commercially, this闭环生态 translates to higher customer stickiness, stronger pricing power, and opens multiple revenue growth avenues.
The technological领先优势 is demonstrated by its globally unique, trillion-parameter, cross-modal medical imaging foundation model, iMedImage®, launched in 2025. As the world's first model of its scale and type, it sets a technical benchmark. It overcomes the limitation of traditional AI handling single imaging modalities by covering 19 types, including CT, MRI, ultrasound, pathology, and chromosome analysis, addressing over 90% of clinical imaging scenarios. Its underlying architecture's generality and adaptability break the industry's reliance on developing solutions from scratch for fragmented applications, providing a reusable technical base for expansion into multiple disease areas and creating a significant first-mover advantage.
From a comparative perspective, DIAGENS-B combines the attributes of an "AI platform" and a "medical device leader," possessing both software and hardware capabilities. Its foundational model capabilities can be likened to platform companies like Palantir. As of September 30, 2025, DIAGENS-B's products were deployed in over 400 medical institutions across 31 Chinese provinces, with a 40% penetration rate among the top 100 hospitals in China. This extensive network of leading hospitals not only forms a solid revenue base but also creates a self-reinforcing "data flywheel": each clinical image input continuously refines and optimizes the iMedImage® model, enhancing its intelligence and accuracy in real-world settings. This logic aligns with Palantir's model of embedding its AIP platform into core decision-making processes, using data to strengthen its competitive moat.
More disruptively, DIAGENS-B has moved beyond the traditional sales-driven growth model of medical device companies. Reportedly, endorsement and promotion by senior physicians in top-tier hospitals have enabled a "physician advocacy, clinically self-driven" customer acquisition model in core markets. Product adoption relies less on large sales teams and more on genuine clinical口碑 and professional endorsement from hospitals. This "de-sales" light-asset expansion path elevates its business model from "selling equipment" to "licensing technology," ensuring a continuous stream of training data and self-sustaining commercial momentum.
In terms of capital market positioning, DIAGENS-B holds the稀缺 value of being the "first large medical imaging model stock." Within the current HKEX landscape, few companies combine high clinical necessity, foundational large model technology, and a clear profit model. Its unique "first stock" status is poised to attract long-term capital focused on the core AI healthcare赛道.
**2. Commercial Validation: Core Product Leadership and High-Margin Growth** The core growth thesis for DIAGENS-B ultimately rests on verifiable performance and a sustainable commercial闭环. Data from its listing documents reveals a dual-engine驱动格局: a solid, leading core business coupled with the emergence of new growth engines, providing strong fundamental support for long-term value.
Firstly, its core products hold the leading market share, validating commercial execution and building comprehensive competitive barriers. According to Frost & Sullivan, based on 2024 sales revenue, DIAGENS-B ranked first in the Chinese chromosome karyotype analysis market with a 30.6% share, demonstrating significant leadership. This position is reinforced by a systematic product ecosystem built around the core karyotype analysis scenario, covering "intelligent equipment – supporting software – reagents/consumables – technology licensing." Through precise tiered commercialization strategies, the company achieves deep penetration across different levels of the healthcare market.
The AutoVision® software series and配套 medical devices cater to two key market demands: intelligent upgrades for existing equipment and new equipment procurement for expanding markets. Reagents and consumables, as a critical part of the ecosystem, are协同 sold with deployed devices, offering customers a "one-stop" solution that enhances customer retention and repeat purchase frequency, creating a sustainable revenue stream. Furthermore, the flagship AI AutoVision® product, upon obtaining National Medical Products Administration (NMPA) approval, is poised to become China's first—and foreseeably the only—Class III medical device intelligent chromosome karyotype辅助诊断 software. This regulatory稀缺性 grants it a significant准入 advantage. Backed by the Class III certificate, AI AutoVision® will initially target top-tier and leading regional hospitals with the most urgent need for advanced analysis software. Clinical validation and brand辐射效应 from these leading institutions will build credibility for subsequent market expansion downwards. AI AutoVision® aims for technological leadership in high-end segments, while AutoVision® secures the broader market base. This tiered penetration strategy is designed for comprehensive coverage of China's hospital system, building a difficult-to-replicate competitive moat and providing dual momentum for sustainable growth.
Secondly, the large model technology licensing business, with a staggering 469.8% growth rate, has become the primary revenue driver, opening a second growth curve. Listing document data shows revenue grew from RMB 52.844 million in 2023 to RMB 70.352 million in 2024, a 33.1% increase. Revenue for the first three quarters of 2025 surged to RMB 112 million, a year-on-year increase of 469.8%. More importantly, a qualitative shift occurred in the revenue structure: in the first three quarters of 2025, technology licensing revenue accounted for 51.4% of total revenue, surpassing traditional businesses for the first time as the largest revenue source. This segment also boasts a gross margin of 96.5%, highlighting its high-value, technology-driven nature. Meanwhile, revenue from medical imaging software and medical equipment grew 281.2% year-on-year, with sales volumes for AutoVision® and MetaSight® increasing by 40.9% and 160.0% respectively, driven by direct sales and leading to higher average selling prices.
Profitability remains strong, with gross margins of 71.0% in 2023, 65.5% in 2024, and 75.9% for the first three quarters of 2025, underscoring the high value-add of its core technology. This structural shift signals two key points: 1) the company's technology储备 has been successfully transformed into scalable, replicable products and services, validating its commercial path; 2) the commercialization of the iMed MaaS platform and AI all-in-one machines is driving a transition from "equipment sales" to "technology output," evolving the business model from one-time hardware revenue to recurring service fees. This opens a growth potential far exceeding the hardware market and offers greater valuation upside.
**3. Industry Tailwinds and Policy Support: Riding a Confluence of Opportunities** The rise of DIAGENS-B is not accidental but results from strategically capturing dual opportunities: an industry growth cycle and a window of policy support, demonstrating foresight and execution capability.
On one hand, the industry offers a "long slope and thick snow"—a clear, long-term growth runway. Frost & Sullivan projects the Chinese AI healthcare market to grow from its current scale of around RMB 5 billion to surpass RMB 100 billion by 2035, implying over 20-fold growth potential, reflecting the sector's long-term prospects. Notably, the chromosome karyotype analysis niche, where DIAGENS-B has deep expertise, is expected to approach RMB 6 billion by 2035, positioning it as a high-value segment within the precision medicine wave. In the broader context of addressing global healthcare resource misallocation, AI healthcare's core value of improving efficiency and reducing costs has established it as a key sector combining certainty and growth in the eyes of capital markets.
On the other hand, policy tailwinds provide an institutional moat. As a national-level "Little Giant" enterprise specializing in specific fields, DIAGENS-B's development aligns with state strategies promoting equitable medical resource distribution and encouraging self-sufficiency in high-end medical devices. Furthermore, its recognition by the Ministry of Industry and Information Technology as the national leader in AI medical devices for genetics affirms its role as a benchmark in implementing national strategies for下沉 quality medical resources and addressing resource inequality.
**4. Global Ambition: From Chinese Leader to Global Contender** DIAGENS-B's strategic ambitions extend beyond domestic borders. Its配套 intelligent scanning system, MetaSight®, has simultaneously obtained the three major global authoritative certifications: China's NMPA, the European Union's CE mark, and the US FDA. This "triple certification" barrier not only confirms the product's world-class technical quality but also clears regulatory hurdles for its global expansion strategy, paving a compliant path to international markets.
Within the global medical imaging AI competitive landscape, DIAGENS-B, with its unique trillion-parameter foundation model, has achieved a generational leap in technology, possessing the underlying capability to compete with international giants. Drawing parallels with overseas AI healthcare firms that experienced significant市值 increases due to technological breakthroughs and commercial progress—such as Palantir's valuation briefly surpassing the $100 billion mark driven by AI narratives, or Tempus AI's strong reception on Nasdaq fueled by the "AI + precision medicine" concept—DIAGENS-B, as a稀缺 HKEX-listed entity with core large model technology and proven commercial success, warrants significant market anticipation for its post-listing value reassessment and potential valuation re-rating.
**5. Conclusion: Reshaping Global Healthcare's Future** The listing is not an endpoint but the beginning of a new journey. For DIAGENS-B, joining the HKEX provides a broader capital platform and enhanced resource allocation capabilities. For investors, it represents an opportunity to participate in the growth of a genuinely globally competitive AI healthcare leader. For China's AI healthcare industry, the "first stock" benchmark effect of DIAGENS-B will instill confidence and momentum into other innovators focused on underlying technologies.
Looking ahead, DIAGENS-B is accelerating its evolution from the "first large medical imaging model stock" towards becoming a "global enabler of medical intelligence." In the era of deep integration between artificial intelligence and healthcare, DIAGENS-B aims to contribute Chinese wisdom, technology, and solutions to power the intelligent transformation of the global healthcare industry. This represents both the ultimate scope for its commercial value and the best reflection of its mission in this era.